key: cord-0700290-ehqa9sam authors: Whitaker, Heather J; Elgohari, Suzanne; Rowe, Cathy; Otter, Ashley David; Brooks, Tim; Linley, Ezra; Hayden, Iain; Ribeiro, Sonia; Hewson, Jacqueline; Lakhani, Anissa; Clarke, Eleanor; Tsang, Camille; Campbell, Colin NJ; Ramsay, Mary; Brown, Kevin; Amirthalingam, Gayatri title: Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021 date: 2021-05-11 journal: J Infect DOI: 10.1016/j.jinf.2021.04.037 sha: 5821b1a9cc598aebccdac72ec05997b5bacba5c4 doc_id: 700290 cord_uid: ehqa9sam The COVID-19 vaccination programme commenced in England on 8(th) December 2020 primarily based on age; by 7(th) March 2021 approximately 93% of the English population aged 70+ years had received at least 1 dose of either the Pfizer BioNTech or AstraZeneca vaccines. Using a nucleoprotein assay that detects antibodies following natural infection only and a spike assay that detects infection and vaccine-induced responses, we aim to describe the impact of vaccination on SARS-CoV-2 antibody prevalence in English blood donors. The COVID-19 vaccination programme commenced in England on 8 th December 2020 primarily based on age; by 7 th March 2021 approximately 93% of the English population aged 70+ years had received at least 1 dose of either the Pfizer BioNTech or AstraZeneca vaccines. Using a nucleoprotein assay that detects antibodies following natural infection only and a spike assay that detects infection and vaccine-induced responses, we aim to describe the impact of vaccination on SARS-CoV-2 antibody prevalence in English blood donors. [3] . We describe the impact of vaccination rollout on antibody prevalence in blood donors in England. As part of COVID-19 infection monitoring, Public Health England, in collaboration with the National Health Service Blood and Transplant Service has arranged regular collections of plasma from English blood donors to be sent for COVID serology testing; results are reported weekly [4] . Approximately 250 samples per week are collected from each of seven NHS regions. We present seropositivity estimates from 23 rd November 2020 onward, which covers the period of vaccine rollout and the peak of England's B.1.1.7-variant dominated epidemic wave. The vaccination status of donors is not available but parallel testing using a nucleoprotein (Roche N) and a spike (Roche S) assay allows us to monitor trends in natural infection transmission and vaccine-induced seropositivity. Nucleoprotein assays (Roche N) only detect antibodies post natural infection, whereas spike assays (Roche S) detect both post natural infection and vaccine-induced antibodies. Antibody responses to both targets reflect infection/vaccination occurring 2-3 weeks previously given the time taken to generate a SARS-CoV2 antibody response [5] . We have shown strong agreement between serological 5 responses using these two assays following natural infection that was sustained 6 months post infection [6] . Seropositivity estimates are calculated on a 4-week rolling basis and are population weighted by NHS region, age group and sex. Estimates are not adjusted for assay sensitivity and specificity, which are estimated to be in excess of 97% and 99.8% respectively [7, 8] . Additionally, estimates are compared against vaccine uptake, which is calculated using the Survey for the period 18 th February -14 th March, based on a single spike target based assay [9] . Roche N seropositivity was considerably lower at 14.5% (95% CI 13.7% -15.4%). Based on Roche S assay results, seroprevalence has been clearly increasing across all age groups from survey weeks 7 th December 2020 -3 rd January 2021 (Figure 1 ). For the most recent 4-week period, the population weighted seroprevalence was highest in the age 70-84 group at 93.5% (95% CI 90.9% -95.4%). In parallel, the Roche N assay, a marker for natural infection, showed not only the lowest seroprevalence in the age 70-84 group for the same period at 4.7% (95% CI 3.1% -7.1%), but this also stabilised over successive four week intervals; for example over the period 1 st -31 st January 2021 seropositivity was 5.2% (95% CI 3.1% -8.5%). Seropositivity based on Roche N was highest in the youngest donor cohort and continues to increase, suggesting transmission was ongoing. 6 Cumulative first dose vaccine uptake was 91.6% to the week ending 21 st February, which roughly corresponds with the most recent 4-week period given 2-3 weeks for antibody response (Figure 2 ). The increase in S positive N negative outcomes accelerated from survey weeks 11 th January -7 th February 2021 following a rise in uptake. Note that age 70+ uptake in Figure 2 is weighted by the 70+ donor age distribution, which tails off with age. The vaccine uptake of 8.7% to the week ending 7 th February in those 18-59y is lower than S positive N negative seroprevalence in younger blood donors, suggesting that health and social care workers are over-represented in the latter group. Since vaccine rollout commenced Roche S seropositivity has increasingly risen above Roche N seropositivity and clearly shows trends in vaccine-induced antibodies, especially within the 70-84 age group who were among the first to be targeted for vaccination. Second dose coverage is less an 1% among the oldest donor age group, hence we observe a robust antibody response following a single vaccine dose. Meanwhile Roche N seropositivity in this age group has remained stable, suggestive of vaccine impact. This adds to a growing body of evidence suggestive of vaccine impact in the UK population [10] . safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers Statement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines The official UK Government website for data and insights on Coronavirus (COVID-19). Vaccinations in United Kingdom National flu and COVID-19 surveillance reports Robust Antibody Responses in 70-80 Year Olds following 1 or 2 Doses of Pfizer Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers Head-to-head benchmark evaluation of the sensitivity and specificity of five immunoassays for SARS-CoV-2 serology on >1500 samples Coronavirus (COVID-19) Infection Survey antibody data for the UK Covid-19: Is vaccination roll out reducing cases and deaths in the UK?